We are excited to announce the successful completion of data collection for the ADHD Remote Technology study of cardiometabolic risk factors and medication adherence (ART-CARMA)!
On 18th December 2025, the last ART-CARMA participant completed their 12-month remote monitoring period. Each of the 305 adults with ADHD, recruited by the study teams at King’s College London (KCL) in the UK and Vall d’Hebron Institute of Research (VHIR) in Spain, contributed both passive and active remote monitoring data that were collected using smartphones and the wearable device EmbracePlus.
Participants started their study period prior to starting medication treatment, allowing these data to capture changes throughout treatment initiation, titration and the first year on medication.
Two new papers published!
Research Fellow Dr Yuezhou Zhang and the team examined real-world changes in adults between off-medication and on-medication phases, using data from the first 176 participants who finished their remote monitoring study period.
Read the full paper in Nature Magazine Translational Psychiatry here: Remote monitoring of wide-ranging real-world changes in adults following ADHD medication initiation | Translational Psychiatry
PhD student Alice Barnes and the team investigated perspectives of pharmacological treatment including medication responses, titration experiences and subsequent medication use, adherence to treatment and reasons for (dis)continuation in 25 adults with ADHD who participated in semi-structured interviews.
Read the full paper in Psychiatry Research here: Perceptions of adults with ADHD on pharmacological treatment initiation and subsequent adherence: a thematic analysis – ScienceDirect
What’s next?
The collection of a dataset that captures real-world changes and perspectives during the first year of treatment, represents a significant step forward in enabling a better understanding of medication effects, adherence, physical activity and cardiometabolic health in adults with ADHD. Now that data collection is complete, our research team will be analysing the full dataset to investigate factors that influence these outcomes. We hope our findings will provide valuable insights that will contribute to improved care, treatment and prevention approaches.
We would like to thank you our amazing study participants, research teams at KCL and VHIR, ADHD clinics, Empatica and ADDISS for making this milestone possible. Stay tuned and visit KCL’s ADHD Remote Technology (ART) team’s LinkedIn for exciting updates!
Back to blog